logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Today at 2 PM, Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

Akero Therapeutics Presented at the H.C. Wainwright 7th Annual NASH Conference Indeed, today, Akero Therapeutics ( AKRO ) presented virtually at the H.C. Wainwright 7th Annual NASH Conference on Tuesday, October 24, 2023, at 12:00 p.m. E.T. A live webcast...

Read More

October 24, 2023

0

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Longeveron in the NEWS On May 9, 2023, Longeveron ( LGVN ) announced new long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome ( HLHS ). What is Hypoplastic Left Heart Syndrome...

Read More

May 9, 2023

0

Cassava Sciences Inc: Today's Press Releases

Cassava Sciences Inc Press Release Related to Positive Biomarker Data  Cassava Sciences Inc ( SAVA ) announced today, in a press release , positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of...

Read More

July 29, 2021

0

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

Intercept Pharmaceuticals  Intercept Pharmaceuticals Inc ( ICPT ) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics aimed at treating progressive non-viral liver diseases, including primary biliary cholangitis ( PBC ), nonalcoholic steatohepatitis ( NASH )...

Read More

May 19, 2023

0

Celmatix Inc: Revolutionizing Fertility Treatments

Celmatix Inc. Celmatix Inc., announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor ( FSHR ) agonist drug. The innovative investigational product has the potential to revolutionize fertility...

Read More

June 27, 2023

0

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.  

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc ( ABBV ) announced detailed results  published in The Lancet  evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome...

Read More

November 17, 2023

0

Bayer & BlueRock Therapeutics: A First Neuronal Stem Cell Therapy to Show Positive Results in Phase I Clinical Study for Parkinson’s Disease    

Bayer and BlueRock Therapeutics Berlin, Germany and Cambridge, M.A., U.S.A., June 28, 2023 –  Bayer AG ( BAYRY ) and its subsidiary firm BlueRock Therapeutics LP  announced positive top-line results from a Phase I clinical trial of the investigational drug...

Read More

June 29, 2023

0

The U.S.FDA Granted CellTrans Inc., Approval of its Product Lantidra for the Treatment of Type 1 Diabetes

CellTrans Inc FDA Approval for Lantidra for Type 1 Diabetes The U.S. Food and Drug Administration ( FDA ) approved CellTrans Inc  treatment Lantidra, the first allogeneic pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treatment...

Read More

June 30, 2023

0

BeiGene Ltd and EUSA Pharma Product QARZIBA® Approval from China NMPA. See Also: Sagimet Sciences and NASH  

BeiGene Ltd and EUSA Pharma Receive Approval from China NMPA for QARZIBA ®   BeiGene Ltd ( BGNE ) and  EUSA Pharma announced that China National Medical Products Administration ( NMPA ) has granted QARZIBA® (dinutuximab beta) conditional approval for...

Read More

August 17, 2021

0

The US FDA Granted Fast Track Designation for Sutro Biopharma Product STRO-002

Sutro Biopharma Inc Granted Fast Track Designation for STRO-002 by the US FDA Sutro Biopharma Inc ( STRO ) announced that the U.S. FDA granted Fast Track designation for its STRO-002 - a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC),...

Read More

August 18, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 107
  • 108
  • 109
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy